Sorafenib With Irinotecan in Metastatic Colorectal Cancer (mCRC) and K-RAS Mutation

Exclusion Criteria

• •Gilbert's disease
• •Brain metastases or carcinomatous symptomatic meningitis
• •Exclusive bone metastasis
• •Previous cancers not considered as cured in the 5 years before inclusion (except for baso-cellular skin carcinoma) Surgery (except diagnostic biopsy) or radiotherapy within 4 weeks before inclusion
• •Disorders of the cardiac rhythm requiring an anti-asynchronous treatment (except beta blockers or digoxine within the framework of a chronic auricular fibrillation), unstable coronaropathy or myocardial infarction \< 6 months, congestive cardiac failure \> Rank II NYHA (Grade 2), uncontrolled arterial hypertension
• •Previous epilepsy crises requiring long term antiepileptic treatment Previous organ transplant requiring immunosuppressor treatment Severe bacterial or fungus infection (\> Grade 2 NCI CTC version 3) Known HIV Infection
• •Long term treatment by known inductors of the CYP 3A4 like Rifampicin, Millepertuis (hypericum perforatum), Phenytoin, Carbamazepin, Phenobarbital, Dexamethasone et Ketonazole
• •Known allergy to one of the therapeutic agents
• •Reasons (psychological, family, social or geographical) that could compromise the participation of the patient in the study
• •Intestinal malabsorption or gastro-intestinal surgery being able to affect Sorafenib absorption. Occlusive or sub-occlusive syndrome.
• •Dysphagic patient or patient not being able to take treatment by orally inflammatory
• •Chronic digestive disease involving chronic diarrhoea (NCI N+Bethesda \>= 1.2g)
• •Participation in another clinical trial within 30 days before the start of this study
• •Other concomitant experimental drugs or other concomitant anticancer agents (except Irinotecan and Sorafenib)
• •Medical or psychological state that in the opinion of the investigator will not allow the patient to terminate the study or to understand and sign the informed consent form
• •Pregnancy and breast-feeding